US Orthopaedics companies face fresh round of scrutiny from DoJ (Department of Justice) antitrust arm
This article was originally published in Clinica
Stocks in orthopaedics took a beating early this week following news that the sector has once again come under the microscope of the US Department of Justice's (DoJ) antitrust arm.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.